Review on gene and cell therapies in prostate cancer treatment: prospects and challenges

Journal of Translational Genetics and Genomics, Journal Year: 2025, Volume and Issue: 9(2), P. 62 - 75

Published: March 21, 2025

Gene and cell therapies have emerged as innovative therapeutic strategies, offering a new paradigm in the treatment of prostate cancer. This review explores current state gene therapies, including their mechanisms, applications, challenges faced clinical translation. The article selection was based on 2020 preferred reporting items for systematic reviews meta-analyses (PRISMA). Eighty-four (84) articles (published English between 2018 2024) from standard electronic databases were extracted reviewed. Key approaches such viral vector-mediated delivery, CRISPR-Cas9 editing, suicide genes, cell-based like CAR T therapy, dendritic vaccines that target specific tumor antigens These promise to enhance efficacy with few challenges, off-target effects, limited delivery efficiency, immune-related toxicities associated delivery. Advances cells, nanoparticle-based systems, epigenetic modulation are potential solutions these challenges. Combination involving immunotherapies oncolytic viruses hold synergistic effects. Certain critical regulatory, ethical, accessibility issues must be addressed ensure safe equitable deployment therapies. Continued research innovation streamlined regulatory pathways will crucial realizing full treating Overcoming fears confronting worldwide might facilitate stream personalized medicine oncology.

Language: Английский

---

Temporal dynamics of lymphocytes in prostate cancer patients treated with proton therapy

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15

Published: April 16, 2025

Radiotherapy can be both immunosuppressive and immunostimulatory. Radiation-induced lymphopenia (RIL) is an ongoing challenge in cancer treatment. We investigated weekly changes the absolute lymphocyte count (ALC) during proton radiotherapy, evaluating effects of different dosage, fractionation schedules, pelvic node irradiation (PNI). Prostate patients were prospectively chosen for this study, due to their relatively homogenous treatment plans. Treatment protocols categorized into three groups: Group A (n=52) received 36.25 Gy/5-fractions, B (n=60) underwent 63 Gy/21-fractions group C (n=69) plus PNI. To account individual characteristic differences, a new categorization method was made, according change ALC relative baseline. Lymphopenia (ALC < 1000 K/μL) developed 8%, 17% 84% groups A, B, C, respectively. An initial increase occurred 44%, 47% 28% respectively, declined with proceeding fractions. Patients PNI had most pronounced reduction Increased dosage led higher incidence lymphopenia. Understanding which factors influence particle therapy vital leveraging immune-enhancing while minimising its impacts.

Language: Английский

---

Steroid receptors in hormone dependent or sensitive cancers: The field of play now and looking forward

The Journal of Steroid Biochemistry and Molecular Biology, Journal Year: 2024, Volume and Issue: 245, P. 106637 - 106637

Published: Nov. 13, 2024

Language: Английский

---